ProfileGDS5678 / 1431026_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 72% 75% 73% 72% 77% 74% 73% 71% 71% 73% 72% 73% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6237573
GSM967853U87-EV human glioblastoma xenograft - Control 24.587572
GSM967854U87-EV human glioblastoma xenograft - Control 34.9308275
GSM967855U87-EV human glioblastoma xenograft - Control 44.8627173
GSM967856U87-EV human glioblastoma xenograft - Control 54.5926572
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0529877
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7454874
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.651673
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4874671
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4389671
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6866673
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.6225372
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.722673
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6803373